An initiative to transition sales of the pirfenidone product アイ スーリュイ from a distributor-led model to a direct-sales model operated by a dedicated in-house sales team, with the aim of driving sales growth, improving profit margins and enhancing service quality for patients and physicians by expanding the sales workforce.